Jon Faiz  Kayyem net worth and biography

Jon Kayyem Biography and Net Worth

Director of Inhibrx Biosciences

Dr. Kayyem has served as a member of our Board since April 2018. He is the founder of GenMark Diagnostics Inc. (“GenMark”) and from May 2010 until February 2018, Dr. Kayyem served in various leadership positions at GenMark including Senior Vice President of Research and Development, Chief Scientific Officer, President, and Chief Executive Officer as the company evolved from Osmetech plc. In 2018, Dr. Kayyem became a consultant to GenMark’s board of directors and executive team. In March 2021, GenMark agreed to merge with Roche, which subsequently acquired GenMark through a tender offer. In 2006, Dr. Kayyem founded and served as a member of the board of directors of privately-held Calimmune, Inc. until its acquisition by CSL Behring in 2017. In 1995, he founded Clinical Micro Sensors, Inc. to commercialize technical innovations he developed while serving as a Senior Research Fellow at the California Institute of Technology (“Caltech”). In 2000, Clinical Micro Sensors, Inc. was sold to Motorola, Inc. and was subsequently purchased by Osmetech plc in 2005. From June 2000 until December 2004, Dr. Kayyem served as Vice President of Life Sciences at Motorola. In October 2004, he co-founded the biotechnology fund management company, Efficacy Capital Limited, and, until September 2009, served as a managing partner. Dr. Kayyem currently serves as a member of the board of directors of Biodesix, Inc. He also currently serves, or has served, as a director or advisor on various non-public company boards, including non-profit and educational institutions. Dr. Kayyem received a combined B.S. and M.S. in Molecular Biophysics and Biochemistry from Yale University and a Ph.D. in Molecular Biology from Caltech. We believe that Dr. Kayyem’s extensive experience as an executive and serving on other boards of directors in the biotechnology and biotherapeutic industry qualifies him to serve as a member of our Board of Directors.

What is Jon Faiz Kayyem's net worth?

The estimated net worth of Jon Faiz Kayyem is at least $4.47 million as of November 19th, 2024. Dr. Kayyem owns 51,093 shares of Inhibrx Biosciences stock worth more than $4,466,039 as of December 5th. This net worth approximation does not reflect any other assets that Dr. Kayyem may own. Learn More about Jon Faiz Kayyem's net worth.

How do I contact Jon Faiz Kayyem?

The corporate mailing address for Dr. Kayyem and other Inhibrx Biosciences executives is 11025 N. TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. Inhibrx Biosciences can also be reached via phone at 858-795-4220 and via email at [email protected]. Learn More on Jon Faiz Kayyem's contact information.

Has Jon Faiz Kayyem been buying or selling shares of Inhibrx Biosciences?

Jon Faiz Kayyem has not been actively trading shares of Inhibrx Biosciences over the course of the past ninety days. Most recently, on Tuesday, November 19th, Jon Faiz Kayyem bought 69,686 shares of Inhibrx Biosciences stock. The stock was acquired at an average cost of $14.23 per share, with a total value of $991,631.78. Following the completion of the transaction, the director now directly owns 51,093 shares of the company's stock, valued at $727,053.39. Learn More on Jon Faiz Kayyem's trading history.

Who are Inhibrx Biosciences' active insiders?

Inhibrx Biosciences' insider roster includes Brendan Eckelman (Insider), Jeffrey Jensen (EVP & Chief Clinical Devel. Officer), Jon Kayyem (Director), Mark Lappe (Founder), Mark Lappe (CEO), and Kristiina Vuori (Director). Learn More on Inhibrx Biosciences' active insiders.

Are insiders buying or selling shares of Inhibrx Biosciences?

During the last twelve months, insiders at the sold shares 1 times. They sold a total of 350,000 shares worth more than $11,287,500.00. The most recent insider tranaction occured on October, 7th when Major Shareholder Global Investors Lp Viking sold 350,000 shares worth more than $11,287,500.00. Insiders at Inhibrx Biosciences own 17.1% of the company. Learn More about insider trades at Inhibrx Biosciences.

Information on this page was last updated on 10/7/2025.

Jon Faiz Kayyem Insider Trading History at Inhibrx Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/19/2024Buy69,686$14.23$991,631.7851,093View SEC Filing Icon  
6/5/2024Buy57,549$17.32$996,748.681,150,410View SEC Filing Icon  
1/23/2023Sell9,500$25.26$239,970.003,224,301View SEC Filing Icon  
12/21/2022Sell9,500$27.02$256,690.003,233,801View SEC Filing Icon  
11/21/2022Sell9,500$29.89$283,955.003,243,301View SEC Filing Icon  
10/21/2022Sell9,500$30.13$286,235.003,252,801View SEC Filing Icon  
See Full Table

Jon Faiz Kayyem Buying and Selling Activity at Inhibrx Biosciences

This chart shows Jon Faiz Kayyem's buying and selling at Inhibrx Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Inhibrx Biosciences Company Overview

Inhibrx Biosciences logo
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.
Read More

Today's Range

Now: $87.41
Low: $81.49
High: $89.43

50 Day Range

MA: $61.01
Low: $28.36
High: $87.41

2 Week Range

Now: $87.41
Low: $10.81
High: $89.43

Volume

275,711 shs

Average Volume

261,355 shs

Market Capitalization

$1.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18